SAN
DIEGO, July 9, 2024 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that the Company will participate in the following investor
conferences:
- H.C. Wainwright Third Annual Kidney Virtual Conference:
Fireside chat on Monday, July 15,
2024, at 10:30 a.m. ET
(7:30 a.m. PT).
- JonesHealthcare Seaside Summit: Presentation on Monday, July 15, 2024, at 4:00 p.m. ET (1:00 p.m.
PT).
The Company will provide a corporate update and present new
analyses from the third cohort of patients in its ongoing Phase
1b multiple-ascending dose (MAD)
clinical trial of RGLS8429 for the treatment of autosomal dominant
polycystic kidney disease (ADPKD). The live events and replays of
the presentations will be available under "Events and
Presentations" through the investor relations section of the
Company's website at https://ir.regulusrx.com/events and
archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS)
is a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting microRNAs. Regulus
has leveraged its oligonucleotide drug discovery and development
expertise to develop a pipeline complemented by a rich intellectual
property estate in the microRNA field. Regulus maintains its
corporate headquarters in San Diego,
CA.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
associated with the Company's RGLS8429 program and preclinical
pipeline, the potential that RGLS8429 may be eligible for an
Accelerated Approval pathway, the expected timing for reporting
topline data, and the timing and future occurrence of other
preclinical and clinical activities. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the risk that the
approach we are taking to discover and develop drugs is novel and
may never lead to marketable products, that preliminary or topline
results are based on a preliminary analysis of key efficacy and
safety data, and such data may change following a more
comprehensive review of the data related to the clinical trial and
may not be indicative of future results, the FDA has not designated
RGLS8429 for an Accelerated Approval pathway and such designation
may not lead to a faster development, regulatory review or approval
process and does not increase the likelihood that RGLS8429 will
receive marketing approval, the risk that preclinical and clinical
studies may not be successful, risks related to regulatory review
and approval, risks related to our reliance on third-party
collaborators and other third parties, risks related to
intellectual property, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, the risk that additional
toxicology data may be negative, and risks related to our ability
to successfully secure and deploy capital. These and other risks
are described in additional detail in Regulus' filings with the
Securities and Exchange Commission, including under the "Risk
Factors" heading of Regulus' quarterly report on Form 10-Q for the
quarter ended March 31, 2024. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Regulus undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-participation-at-two-healthcare-investment-conferences-302191389.html
SOURCE Regulus Therapeutics Inc.